108 related articles for article (PubMed ID: 10554877)
1. A diminution of delta9-tetrahydrocannabinol modulation of dynorphin A-(1-17) in conjunction with tolerance development.
Mason DJ; Lowe J; Welch SP
Eur J Pharmacol; 1999 Sep; 381(2-3):105-11. PubMed ID: 10554877
[TBL] [Abstract][Full Text] [Related]
2. Cannabinoid modulation of dynorphin A: correlation to cannabinoid-induced antinociception.
Mason DJ; Lowe J; Welch SP
Eur J Pharmacol; 1999 Aug; 378(3):237-48. PubMed ID: 10493099
[TBL] [Abstract][Full Text] [Related]
3. Antisense oligodeoxynucleotides to the kappa1 receptor enhance delta9-THC-induced antinociceptive tolerance.
Rowen DW; Embrey JP; Moore CH; Welch SP
Pharmacol Biochem Behav; 1998 Feb; 59(2):399-404. PubMed ID: 9476987
[TBL] [Abstract][Full Text] [Related]
4. Dynorphin B and spinal analgesia: induction of antinociception by the cannabinoids CP55,940, Delta(9)-THC and anandamide.
Houser SJ; Eads M; Embrey JP; Welch SP
Brain Res; 2000 Feb; 857(1-2):337-42. PubMed ID: 10700588
[TBL] [Abstract][Full Text] [Related]
5. The antinociceptive effect of Delta9-tetrahydrocannabinol in the arthritic rat.
Cox ML; Welch SP
Eur J Pharmacol; 2004 Jun; 493(1-3):65-74. PubMed ID: 15189765
[TBL] [Abstract][Full Text] [Related]
6. Involvement of kappa/dynorphin system in the development of tolerance to nicotine-induced antinociception.
Galeote L; Maldonado R; Berrendero F
J Neurochem; 2008 May; 105(4):1358-68. PubMed ID: 18221370
[TBL] [Abstract][Full Text] [Related]
7. Concurrent bullatine A enhances morphine antinociception and inhibits morphine antinociceptive tolerance by indirect activation of spinal κ-opioid receptors.
Huang Q; Sun ML; Chen Y; Li XY; Wang YX
J Ethnopharmacol; 2017 Jan; 196():151-159. PubMed ID: 27989510
[TBL] [Abstract][Full Text] [Related]
8. Aconitum-Derived Bulleyaconitine A Exhibits Antihypersensitivity Through Direct Stimulating Dynorphin A Expression in Spinal Microglia.
Li TF; Fan H; Wang YX
J Pain; 2016 May; 17(5):530-48. PubMed ID: 26762790
[TBL] [Abstract][Full Text] [Related]
9. Two distinctive antinociceptive systems in rats with pathological pain.
Mao J; Price DD; Lu J; Keniston L; Mayer DJ
Neurosci Lett; 2000 Feb; 280(1):13-6. PubMed ID: 10696800
[TBL] [Abstract][Full Text] [Related]
10. Characterization of anandamide-induced tolerance: comparison to delta 9-THC-induced interactions with dynorphinergic systems.
Welch SP
Drug Alcohol Depend; 1997 Apr; 45(1-2):39-45. PubMed ID: 9179505
[TBL] [Abstract][Full Text] [Related]
11. Possible involvement of dynorphin A-(1-17) release via mu1-opioid receptors in spinal antinociception by endomorphin-2.
Mizoguchi H; Watanabe H; Hayashi T; Sakurada W; Sawai T; Fujimura T; Sakurada T; Sakurada S
J Pharmacol Exp Ther; 2006 Apr; 317(1):362-8. PubMed ID: 16394196
[TBL] [Abstract][Full Text] [Related]
12. A role for central cannabinoid and opioid systems in peripheral delta 9-tetrahydrocannabinol-induced analgesia in mice.
Reche I; Fuentes JA; Ruiz-Gayo M
Eur J Pharmacol; 1996 Apr; 301(1-3):75-81. PubMed ID: 8773449
[TBL] [Abstract][Full Text] [Related]
13. Involvement of dynorphin B in the antinociceptive effects of the cannabinoid CP55,940 in the spinal cord.
Pugh G; Mason DJ; Combs V; Welch SP
J Pharmacol Exp Ther; 1997 May; 281(2):730-7. PubMed ID: 9152379
[TBL] [Abstract][Full Text] [Related]
14. Characterization of anandamide- and fluoroanandamide-induced antinociception and cross-tolerance to delta 9-THC after intrathecal administration to mice: blockade of delta 9-THC-induced antinociception.
Welch SP; Dunlow LD; Patrick GS; Razdan RK
J Pharmacol Exp Ther; 1995 Jun; 273(3):1235-44. PubMed ID: 7791096
[TBL] [Abstract][Full Text] [Related]
15. Dynorphin-independent spinal cannabinoid antinociception.
Gardell LR; Ossipov MH; Vanderah TW; Lai J; Porreca F
Pain; 2002 Dec; 100(3):243-248. PubMed ID: 12467995
[TBL] [Abstract][Full Text] [Related]
16. The role of endogenous opioids in enhancing the antinociception produced by the combination of delta 9-tetrahydrocannabinol and morphine in the spinal cord.
Pugh G; Smith PB; Dombrowski DS; Welch SP
J Pharmacol Exp Ther; 1996 Nov; 279(2):608-16. PubMed ID: 8930163
[TBL] [Abstract][Full Text] [Related]
17. Ovarian sex steroid-dependent plasticity of nociceptin/orphanin FQ and opioid modulation of spinal dynorphin release.
Gupta DS; Kelson AB; Polgar WE; Toll L; Szücs M; Gintzler AR
J Pharmacol Exp Ther; 2001 Sep; 298(3):1213-20. PubMed ID: 11504823
[TBL] [Abstract][Full Text] [Related]
18. Possible involvement of dynorphin A release via mu1-opioid receptor on supraspinal antinociception of endomorphin-2.
Sakurada S; Sawai T; Mizoguchi H; Watanabe H; Watanabe C; Yonezawa A; Morimoto M; Sato T; Komatsu T; Sakurada T
Peptides; 2008 Sep; 29(9):1554-60. PubMed ID: 18571771
[TBL] [Abstract][Full Text] [Related]
19. Interactions between delta 9-tetrahydrocannabinol and kappa opioids in mice.
Smith PB; Welch SP; Martin BR
J Pharmacol Exp Ther; 1994 Mar; 268(3):1381-7. PubMed ID: 8138952
[TBL] [Abstract][Full Text] [Related]
20. Lappaconitine, a C18-diterpenoid alkaloid, exhibits antihypersensitivity in chronic pain through stimulation of spinal dynorphin A expression.
Sun ML; Ao JP; Wang YR; Huang Q; Li TF; Li XY; Wang YX
Psychopharmacology (Berl); 2018 Sep; 235(9):2559-2571. PubMed ID: 29926144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
